Pharmacometrics integrates knowledge of drug exposure and response to support dose selection, safety, and efficacy. Our global team applies advanced population pharmacokinetic (PopPK), pharmacokinetic-pharmacodynamic (PK/PD), and exposure–response modeling to inform development decisions and accelerate clinical programs.
We deliver the full range of pharmacometrics analyses required for regulatory submissions, helping sponsors optimize trial design, support dose justification, and generate evidence across diverse patient populations, including special populations, such as pediatric and rare disease patients. These approaches are increasingly central to model-informed drug development (MIDD) and evolving regulatory frameworks such as ICH M15.
